Home > Boards > US Listed > Biotechs > Teva Pharmaceutical (TEVA)

An article on SA recently mentioned that despite

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Teva, Amazon Web Services and Onica Announce Collaboration to Support Teva’s Digihaler® Portfolio Business Wire - 10/21/2020 8:00:00 AM
Shield Therapeutics: Peer Teva Pharmaceutical Industries Withdraws Oppositions to Patents Dow Jones News - 10/19/2020 3:14:00 AM
iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors GlobeNewswire Inc. - 10/15/2020 7:30:10 AM
Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY® (fremanezumab-vfr... Business Wire - 10/7/2020 8:00:00 AM
Teva Canada annonce la mise en marché d’Aermony RespiClickMC, un nouveau dispositif novateur dans le traitement de l’ast... Business Wire - 10/5/2020 8:00:00 AM
Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthma PR Newswire (Canada) - 10/5/2020 8:00:00 AM
Teva Canada annonce la mise en marché d'Aermony RespiClickMC, un nouveau dispositif novateur dans le traitement de l'asthme ... PR Newswire (Canada) - 10/5/2020 8:00:00 AM
Teva Launches First Generic Versions of HIV-1 Treatments TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg... Business Wire - 10/2/2020 8:00:00 AM
Teva to Host Conference Call to Discuss Third Quarter 2020 Financial Results at 8 a.m. ET on November 5, 2020 Business Wire - 10/1/2020 11:06:00 AM
Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate & salmeterol) Inhalation Powder ... Business Wire - 9/21/2020 8:00:00 AM
First Long-Term Data on the use of AJOVY® (fremanezumab-vfrm) Injection in Patients with Migraine Published in Neurology Business Wire - 9/15/2020 8:00:00 AM
Teva to Present New Data at The MDS Virtual Congress 2020 & Psych Congress 2020 Virtual Experience Evaluating Long-Term Treat... Business Wire - 9/14/2020 8:00:00 AM
Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 & Psych Congress 2020 Virtu... Business Wire - 9/8/2020 8:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/3/2020 4:10:25 PM
Indictment Came After Failed DOJ, Teva Talks -- WSJ Dow Jones News - 8/28/2020 3:02:00 AM
Teva's Indictment Came After Talks Faltered with Justice Department Dow Jones News - 8/27/2020 5:21:00 PM
Teva Indicted in Price Case -- WSJ Dow Jones News - 8/26/2020 3:02:00 AM
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges -- 4th Update Dow Jones News - 8/25/2020 10:14:00 PM
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges -- 3rd Update Dow Jones News - 8/25/2020 8:43:00 PM
Statement in Response to News of the Indictment of Teva USA Business Wire - 8/25/2020 8:39:00 PM
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges -- 2nd Update Dow Jones News - 8/25/2020 7:57:00 PM
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges -- Update Dow Jones News - 8/25/2020 6:57:00 PM
Teva Pharmaceutical's U.S. Unit Indicted on Price-Fixing Charges Dow Jones News - 8/25/2020 6:31:00 PM
Teva Canada announces product availability of AJOVY™ PR Newswire (Canada) - 8/19/2020 8:00:00 AM
Teva Canada annonce la mise en marché d'AJOVY(MC) PR Newswire (Canada) - 8/19/2020 8:00:00 AM
investora2z   Thursday, 11/28/13 12:35:25 PM
Re: None
Post # of 3527 
An article on SA recently mentioned that despite the patent cliff worries, the company's target price has been raised by Susquehanna, and Soros Fund Management has increased its equity stake. The generic segment is expected to do better over the years as there is a global shift from patented drugs towards the generic ones. The growth in this segment over the next few years will surely help Teva as more than half its revenues come from generics. Even if Teva is able to maintain its market share in the US generics market, it will grow at a decent pace over the next few years. Copaxone patent expiry will surely hit the sales, but new launches and better performance from existing products can help make up for the loss. It got an Orphan designation for Treanda in indolent B-cell non-Hodgkin lymphoma, and has six months of pediatric exclusivity for the drug. Performance by ProAir and Qvar is also expected to help. Entry into other segments, and its strong pipeline will also lead to tangible results over the next few years. The R&D spending is being increased to support future growth. The next few years are likely to improve the margins of the company as it is focusing on making itself more efficient and cutting down the costs. 70% of the expected cost savings will be achieved in the upcoming three years. The forward P/E is reasonable and the dividend yield is also better than the industry average. Dr. Frost has been extremely active in exploring collaboration opportunities between his companies. Cocrystal Discovery, a company where Teva and Opko (OPK) have a stake, recently merged with Biozone pharmaceuticals (BZNE) to take advantage of expected synergies. Teva, meanwhile, remains stuck in the $6 range between $36 and $42. It will require something major to breakout beyond this strong resistance.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences